FDA Approved & Pharmacopeial Drug Library

Description: New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3450 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
MCE FDA Approved & Pharmacopeial Drug Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 3364 compounds supplied in 10 mM solution, 63 compounds supplied in 2 mM solution and 23 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 3450 marketed drugs for high throughput screening (HTS) and high content screening (HCS).
• All drugs were from approved institutions such as FDA, EMA, NMPA, PMDA, or pharmacopoeia such as USP, BP, EP, JP, etc.
• Used in the research of oncology, cardiology, anti-inflammatory, immunology, dermatology, endocrinology, neurology, and more.
• A useful tool for researching new targets of marketed old drugs.
• Structurally diverse, bioactive, and cell permeable.
• More detailed compound information with structure, IC50, and brief introduction.
• NMR and HPLC validated ensure high purity.
• All compounds are in stock and continuously updated.

Formulation: A collection of 3450 marketed and pharmacopeial drugs compounds supplied as pre-dissolved Solutions or SolidSolution:3364 compounds supplied in 10 mM solution,63 compounds supplied in 2 mM solution,23 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L066-100
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L066-100
• Green Labware: Nein
• Verpackungseinheit: 100 μl
• Mengeneinheit: STK